Hainan Guoruikang Biotechnology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hainan Guoruikang Biotechnology Co., Ltd. - overview
Established
2022
Location
-, Hainan, China
Primary Industry
Biotechnology
About
Headquartered in China and founded in 2022, Hainan Guoruikang Biotechnology Co. , Ltd. provides pharmaceutical R&D and CRO services for the healthcare and biotechnology sectors. Its service portfolio includes API synthesis, dosage-form development, analytical testing and clinical research.
The firm serves pharmaceutical developers and research institutions across China. In December 2025, the company closed a round of venture funding from Fujian Venture. The company works with pharmaceutical and biotechnology enterprises to provide CRO services including API synthesis, multi-dosage drug development, analytical and quality studies, clinical research execution and regulatory submission support. The company’s revenue is generated through B2B contracts for CRO services, such as R&D projects, clinical research services, pilot production support and regulatory submission services.
Current Investors
Fujian Venture
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.